Fibrogen's new data eases heart-safety concerns about anemia pill

Fibrogen's new data eases heart-safety concerns about anemia pill

STAT Plus: Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

By ADAM FEUERSTEIN

ADOBE

A pooled safety analysis concludedthe risk of an adverse cardiovascular event was statistically comparable between the Fibrogen drug and placebo or control.

READ MORE